Why join Freenome?
Freenome is a high-growth biotech company developing tests to detect cancer using a standard blood draw. To do this, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to find cancer in its earliest, most-treatable stages.
Cancer is relentless. This is why Freenome is building the clinical, economic, and operational evidence to drive cancer screening and save lives. Our first screening test is for colorectal cancer (CRC) and advanced adenomas, and it’s just the beginning.
Founded in 2014, Freenome has ~400 employees and continues to grow to match the scope of our ambitions to provide access to better screening and earlier cancer detection.
At Freenome, we aim to impact patients by empowering everyone to prevent, detect, and treat their disease. This, together with our high-performing culture of respect and cross-collaboration, is what motivates us to make every day count.
Become a Freenomer
Do you have what it takes to be a Freenomer? A “Freenomer” is a determined, mission-driven, results-oriented employee fueled by the opportunity to change the landscape of cancer and make a positive impact on patients’ lives. Freenomers bring their diverse experience, expertise, and personal perspective to solve problems and push to achieve what’s possible, one breakthrough at a time.
About this opportunity:
At Freenome, we are seeking an Associate Director, Product Management to help grow the Freenome Product Management team. The ideal candidate is someone who seeks to define and deliver innovative clinical diagnostic products that will improve patient outcomes. This person is responsible for all things related to the product strategy, user needs, and the commercialization plan for Freenome’s lunch cancer screening solutions. You are passionate about identifying unmet needs, framing product opportunities, and being a part of a team that delivers tests that make a difference, and you will have a significant impact on the continued growth of an organization dedicated to changing the entire landscape of cancer.
The role reports to the Senior Director, Product Management. This role will be a Hybrid role based in our Brisbane, California headquarters.
What you’ll do:
- In partnership with the Senior Director, Product Management, play a key role in developing the vision and product strategy & lifecycle roadmap for Freenome’s lung cancer screening solutions
- Conduct market research (secondary and primary) to analyze market dynamics and unmet needs of patients, payers, providers, and less traditional healthcare delivery channels
- Ideate and prioritize products that would support patients throughout their lung cancer early detection journey
- Define product lifecycle roadmaps for prioritized products, taking into account the ecosystem of stakeholders involved
- Define the user needs for Freenome’s lung cancer screening blood tests
- Conduct voice of customer research to document and quantify user needs
- Collaborate with Freenome’s R&D team to translate user needs into design inputs
- Work with Freenome’s R&D and clinical development teams to understand how technical capabilities will impact product requirements
- Develop the go-to-market commercialization plan with cross-functional teams (e.g., medical affairs, marketing, sales)
- Research, analyze, and synthesize overall market data to appropriately segment customers and product selection criteria
- Assess competitor offerings and commercial strategies to properly position against and compete in the market
- Lead cross-functional teams to execute on the product and bring a strategic lens to:
- Inform and guide the team’s activities
- Drive cross-functional coordination
- Prioritize deliverables and resource needs
- Problem solve challenges
Must haves:
- Bachelor’s degree; degree in an analytical, technical, or scientific field
- At least 9+ years prior overall relevant experience in product management or commercial (e.g., marketing, sales) roles in the diagnostics and/or healthcare industry
- At least 5+ years leading teams, including at least two years in a Senior Management role
- Broad and in-depth understanding of product management and commercialization for clinical diagnostic products
Nice to haves:
- Advanced degree in an analytical, technical, or scientific field
- At least two years of experience in a business strategy role (e.g., management consulting, corporate strategy)
- Experience with Laboratory Developed Tests (LDT) and In Vitro Diagnostic (IVD) products
- Experience in product management from research & development to clinical validation to commercialization
Benefits and additional information:
The US target range of our base salary for new hires is $182,750 - $275,000. You will also be eligible to receive pre-IPO equity, cash bonuses, and a full range of medical, financial, and other benefits depending on the position offered. Please note that individual total compensation for this position will be determined at the Company’s sole discretion and may vary based on several factors, including but not limited to, location, skill level, years and depth of relevant experience, and education. We invite you to check out our career page @ freenome.com/job-openings/ for additional company information.
Freenome is proud to be an equal-opportunity employer, and we value diversity. Freenome does not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.
Applicants have rights under Federal Employment Laws.
- Family & Medical Leave Act (FMLA)
- Equal Employment Opportunity (EEO)
- Employee Polygraph Protection Act (EPPA)
#LI-HYBRID
What We Do
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer.
We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science.
Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.